True North Labs

Author: labstruenorth@gmail.com

  • FDA Advisory Panel Recommends Expanding Access to Six Peptides Through Compounding

    In a development that could reshape access to peptide therapies, an FDA advisory panel has voted to recommend six peptides for inclusion on the agency’s list of substances eligible for pharmacy compounding. This decision represents a significant step in the ongoing effort to formally integrate peptide therapies into the broader landscape of regulated compounded medicine.

    Compounding pharmacies play an important role in the healthcare system, allowing licensed pharmacists to prepare customized medications tailored to specific patient needs when commercially manufactured products aren’t suitable. When a peptide is added to the FDA’s approved compounding list, it provides a clearer regulatory pathway for pharmacies to legally prepare these substances under proper oversight and quality standards, rather than operating in a legal gray area.

    This panel recommendation is encouraging news for patients and practitioners who have come to rely on peptide therapies for a range of wellness and therapeutic applications. Formal recognition through the compounding pathway can help ensure greater consistency, safety oversight, and quality control compared to unregulated sourcing, giving patients more confidence in the products they receive.

    The move also reflects a broader trend of regulatory bodies taking peptide science seriously as this class of therapeutics continues to grow in both clinical interest and public demand. As research into peptides expands across metabolic health, recovery, and other areas, thoughtful regulatory frameworks like this one help create a more sustainable and trustworthy ecosystem for their responsible use.

    While the panel’s recommendation is not the final step in the process, it signals positive momentum toward clearer rules that could benefit patients, prescribers, and compounding pharmacies alike. True North Labs will continue to monitor developments as the FDA moves through its formal review process.

    This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider regarding any peptide therapy.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel Backs 6 Peptides for Compounding – The American Journal of Managed Care

  • New Phase III Trial Explores Combining Cetuximab with Pembrolizumab for Recurrent Head and Neck Cancer

    New Phase III Trial Explores Combining Cetuximab with Pembrolizumab for Recurrent Head and Neck Cancer

    Researchers have launched a promising new phase III clinical trial designed to explore whether combining two targeted therapies—cetuximab and pembrolizumab—can offer better outcomes for patients facing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This large-scale study represents an important step forward in the ongoing effort to improve treatment options for patients whose cancer has returned or spread after previous therapy.

    Pembrolizumab, an immunotherapy drug, is already a standard treatment that helps the immune system recognize and attack tumor cells. The new trial will test whether adding cetuximab, a monoclonal antibody that targets the EGFR protein found on many tumor cells, can enhance these effects. By blocking EGFR signaling, cetuximab may help slow tumor cell growth, potentially working in tandem with pembrolizumab’s immune-boosting properties to create a more powerful combined treatment approach.

    What makes this trial particularly encouraging is its focus on a patient population that often faces limited treatment options after their cancer has recurred or spread. Head and neck cancers can be especially challenging to treat once they return, so any research aimed at expanding and improving therapeutic combinations offers real hope for better quality of life and outcomes for these patients.

    This phase III design means the trial is a significant, well-structured study capable of generating robust data that could shape future treatment guidelines if the combination proves more effective than pembrolizumab alone. The scientific rationale—pairing an EGFR-targeting antibody with an immune checkpoint inhibitor—reflects a broader trend in oncology toward combination therapies that attack cancer through multiple mechanisms simultaneously.

    As this trial progresses, the oncology community will be watching closely to see whether this combination can meaningfully improve outcomes for patients with recurrent or metastatic HNSCC. Trials like this one are essential building blocks in the continual refinement of cancer care, and their careful, rigorous design offers a path toward evidence-based improvements in treatment. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  • New Clinical Trial Explores Amivantamab Combinations for Early-Stage EGFR-Mutated Lung Cancer

    A new clinical trial has begun recruiting to evaluate a promising treatment approach for patients with resectable, EGFR-mutated non-small cell lung cancer (NSCLC) in Stage II-IIIB. The study will examine whether administering amivantamab—a targeted therapy designed to block signals that help cancer cells grow—together with either lazertinib or a chemotherapy combination of carboplatin and pemetrexed, can help slow or stop tumor growth before surgery.

    NSCLC is the most common form of lung cancer, and mutations in the EGFR gene are among the key drivers of the disease in a significant subset of patients. Researchers have been working to identify treatment combinations that not only target the cancer more precisely but also potentially improve outcomes when used in the neoadjuvant setting, meaning before a patient undergoes surgical removal of the tumor.

    This type of pre-surgical treatment strategy is an area of growing interest in oncology, as shrinking tumors ahead of surgery may make procedures more effective and could potentially improve long-term results for patients. By comparing amivantamab paired with lazertinib against amivantamab paired with traditional chemotherapy, the trial aims to generate valuable data on how these approaches perform relative to one another, giving physicians more information to guide future treatment decisions.

    The initiation of this trial represents another step forward in the broader effort to bring more personalized and effective treatment options to patients with EGFR-mutated lung cancer, a population that often benefits from therapies designed to target the specific genetic changes driving their disease. Trials like this help build the evidence base needed to refine treatment protocols and, over time, expand the toolkit available to oncologists treating this challenging condition.

    As with any clinical trial, results will take time to emerge, and much work remains before conclusions can be drawn about safety and effectiveness. Patients and families interested in learning more about this study can find additional details through the official listing on ClinicalTrials.gov. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  • New Phase III Trial Explores Adding Targeted Immunotherapy to Hodgkin Lymphoma Treatment

    Researchers have launched a phase III clinical trial designed to explore whether adding two advanced therapies, brentuximab vedotin and nivolumab, to standard treatment can improve outcomes for patients with stage I and II classical Hodgkin lymphoma. The trial represents an encouraging step forward in the ongoing effort to refine and personalize cancer care for this typically treatable but still serious form of lymphoma.

    Brentuximab vedotin belongs to a class of medications known as antibody-drug conjugates, which combine the precision of a monoclonal antibody with the cell-killing power of a cytotoxic agent. In this case, the antibody component seeks out CD30, a marker found on the surface of Hodgkin lymphoma cells, and delivers its therapeutic payload directly to those cells. This targeted approach is part of a broader trend in oncology toward therapies that aim to be more selective, potentially sparing healthy tissue compared to traditional chemotherapy alone.

    The trial also incorporates nivolumab, an immunotherapy designed to help the body’s own immune system recognize and respond to cancer cells more effectively. By pairing this immune-boosting approach with brentuximab vedotin, alongside standard chemotherapy regimens and radiation therapy where appropriate, researchers hope to determine whether patients experience improved survival outcomes and potentially fewer long-term side effects compared to standard treatment alone.

    What makes this study particularly promising is its focus on early-stage disease, where the goal is not only to maximize the chances of remission but also to minimize the long-term toxicity that can accompany intensive chemotherapy and radiation. Classical Hodgkin lymphoma already has relatively favorable outcomes compared to many other cancers, and trials like this one reflect the medical community’s continued commitment to pushing those outcomes even further while working to reduce the burden of treatment on patients, especially since Hodgkin lymphoma often affects younger individuals who may face decades of life after treatment.

    Trials such as this one highlight how far cancer research has come in developing more targeted, thoughtfully designed treatment combinations. As enrollment and data collection continue, the oncology community will be watching closely to see whether this combination approach can offer a meaningful step forward for patients facing this diagnosis. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  • New Trial Aims to Sharpen MRSA Treatment by Comparing Two Leading Therapies

    New Trial Aims to Sharpen MRSA Treatment by Comparing Two Leading Therapies

    A newly launched clinical trial is set to bring more clarity to how doctors treat one of the toughest bloodstream infections in modern medicine: methicillin-resistant Staphylococcus aureus, or MRSA. The open-label, randomized controlled trial will directly compare daptomycin, a cyclic lipopeptide antibiotic, with vancomycin, the two most commonly used therapies for this serious infection.

    What makes this study particularly encouraging is its scale and structure. It is registered as an approved sub-study of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial, a large international collaborative effort designed to continuously generate high-quality evidence on how best to treat S. aureus infections. By embedding this comparison within an adaptive platform trial, researchers can efficiently gather robust data while maintaining rigorous scientific standards, potentially accelerating the pace at which clinicians receive actionable answers.

    Daptomycin, a naturally derived cyclic lipopeptide, works differently than traditional antibiotics like vancomycin, targeting bacterial cell membranes in a way that has made it a valuable tool against resistant strains. Head-to-head comparisons like this one help physicians understand not just whether a therapy works, but how it performs relative to established alternatives in real-world clinical settings. For patients facing MRSA bacteremia, a condition that can be life-threatening and challenging to treat, having more precise, evidence-based guidance on therapy selection could meaningfully improve outcomes.

    This kind of comparative effectiveness research reflects the ongoing progress in peptide-based and peptide-adjacent therapeutics within infectious disease medicine. As resistant bacterial strains continue to pose challenges worldwide, trials like this one demonstrate the medical community’s commitment to refining and optimizing the tools already available, rather than simply accepting current standards of care as final. Better data on how these therapies compare could help clinicians make more confident, personalized decisions for patients with serious infections.

    As the SNAP trial platform continues to expand its investigations, findings from this sub-study may offer valuable insights not only for MRSA treatment protocols but also for how adaptive trial designs can be used to answer pressing clinical questions more efficiently. This is a promising step toward more informed, evidence-driven care for a difficult-to-treat infection.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

  • Lilly’s Triple-Agonist Retatrutide Shows Powerful Weight Loss in Pivotal Phase 3 Trial

    Eli Lilly has announced encouraging results from a pivotal Phase 3 trial of retatrutide, its investigational triple agonist peptide designed to target the GLP-1, GIP, and glucagon receptors simultaneously. The trial reported substantial weight loss among participants with obesity, reinforcing the growing body of evidence that multi-receptor agonists may represent a significant step forward in metabolic health treatment.

    Retatrutide’s triple-action mechanism sets it apart from earlier single- or dual-agonist therapies. By engaging three distinct metabolic pathways, the peptide is designed to influence appetite regulation, energy expenditure, and glucose metabolism more comprehensively than previous approaches. The pivotal trial results suggest that this broader mechanism may translate into meaningful clinical benefits for people struggling with obesity and related conditions.

    This development is part of a larger wave of innovation in peptide-based metabolic therapies, following the successes of earlier GLP-1 and dual-agonist medications that have already reshaped obesity treatment over the past few years. Positive pivotal trial data is a critical milestone on the path toward potential regulatory review, and it reflects the continued maturation of peptide science as a serious tool in addressing chronic metabolic disease.

    For patients and clinicians alike, these results add to a growing sense of optimism that future obesity treatments may offer even greater efficacy, potentially improving quality of life and reducing the burden of weight-related health complications for millions of people. As Lilly moves forward with additional data analysis and regulatory planning, retatrutide stands as a promising example of how continued investment in peptide research is expanding the possibilities for metabolic health care.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial – Eli Lilly and Company

  • FDA Advisory Panel Votes to Ease Restrictions on Four Peptides

    FDA Advisory Panel Votes to Ease Restrictions on Four Peptides

    In a promising sign for the peptide research and therapeutic community, an FDA advisory panel has voted to ease restrictions on four peptide compounds. While the full regulatory process still needs to play out, this vote signals a meaningful shift toward more flexible oversight for these substances.

    Advisory panel votes like this one are an important early step in the FDA’s broader regulatory pathway. When a panel recommends loosening restrictions, it often reflects a growing body of evidence and expert confidence that the compounds in question may be safely used under more accessible conditions than previously allowed. This kind of movement can pave the way for expanded research opportunities, more streamlined manufacturing and distribution pathways, and greater clarity for practitioners and companies working in the peptide space.

    For the peptide industry as a whole, actions like this are encouraging because they suggest regulators are actively engaging with the science and reassessing older restrictions in light of newer data. Reduced regulatory friction can translate into more investment in research, expanded formulation options, and potentially broader availability for peptides that have demonstrated a solid safety and efficacy profile through the review process.

    It is worth noting that an advisory panel vote is a recommendation, not a final rule. The FDA typically considers panel input as part of a longer process that may include additional review, public comment periods, and final agency decisions. Still, positive votes like this one are often viewed as a strong indicator of the direction regulatory policy is heading.

    True North Labs will continue to track how this recommendation develops and what it could mean for peptide accessibility going forward. As always, this article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel Votes to Loosen Restrictions for Four Peptides – Pharmaceutical Executive

  • FDA Advisory Panel Backs Expanded Access to Certain Peptide Therapies

    FDA Advisory Panel Backs Expanded Access to Certain Peptide Therapies

    In an encouraging sign for the peptide therapeutics field, an FDA advisory panel has recommended broader use of certain peptide-based treatments. While advisory panel recommendations are not binding, they carry significant weight with regulators and often shape the agency’s final decisions on drug approvals and expanded indications.

    Advisory panels are typically composed of independent medical experts, clinicians, and scientists who review clinical data, safety profiles, and real-world evidence before making recommendations to the FDA. A favorable vote suggests that the panel found the available evidence compelling enough to support wider patient access, which is often the culmination of years of rigorous clinical trial work and data collection.

    For patients and healthcare providers, an endorsement like this can be a meaningful step toward more treatment options becoming available through standard medical channels. Broader regulatory acceptance of peptide therapies also reflects the maturing scientific understanding of how these compounds work in the body, and growing confidence in their safety and efficacy profiles when used appropriately under medical supervision.

    This kind of regulatory momentum is also good news for the broader peptide research community. Positive advisory panel actions can encourage continued investment in peptide science, support further clinical investigation, and help pave the way for additional peptide-based therapies to move through the development pipeline in the future.

    As always, any changes in official FDA guidance or approval status will determine how these therapies become available to patients, and decisions about treatment should always be made in consultation with a qualified healthcare provider. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA panel endorses broader use of certain peptides – BioPharma Dive

  • FDA Advisory Panel Signals Support for Compounded Peptide Access

    FDA Advisory Panel Signals Support for Compounded Peptide Access

    Recent reporting indicates that an FDA advisory panel has recommended allowing pharmacies to continue compounding certain peptides that have not yet received full agency approval. For patients and clinicians who rely on these formulations, this kind of recommendation is an encouraging sign that regulators are weighing practical access alongside safety considerations.

    Compounded peptides have become an important option for patients seeking individualized dosing or formulations not otherwise available through commercially approved products. When an FDA panel signals support for continued compounding, it suggests regulators recognize the value these therapies provide while broader approval processes continue in the background.

    This kind of recommendation often reflects a broader, more collaborative relationship between the peptide industry, compounding pharmacies, and regulatory bodies. Rather than an outright restriction, a favorable panel recommendation can pave the way for continued innovation, giving compounders and manufacturers more clarity on how to responsibly bring these products to patients while safety and quality standards are refined.

    For the wider peptide community, developments like this are meaningful because they help maintain the availability of therapies that many patients and practitioners have come to depend on, while still working within a regulatory framework designed to protect public health. It also underscores an evolving dialogue between the FDA and stakeholders about how best to balance innovation with oversight.

    As always, specific regulatory outcomes can change, and the full details of any FDA panel recommendation should be reviewed through official channels. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel Recommends Compounding Unapproved Peptides – 조선일보

  • Retatrutide Shows Remarkable Weight-Loss Results, Rivaling Surgical Outcomes

    Retatrutide Shows Remarkable Weight-Loss Results, Rivaling Surgical Outcomes

    A new peptide-based therapy called retatrutide is generating excitement in the medical community after clinical trial participants achieved weight loss of up to 30% of their body weight—results that rival those typically seen only with bariatric surgery. According to reporting from UCHealth, this milestone marks one of the most significant advances yet in the rapidly evolving field of weight-management medications.

    Retatrutide works by targeting multiple hormone receptors involved in appetite regulation and metabolism, building on the mechanisms that have made earlier GLP-1-based treatments successful. By acting on additional pathways, researchers believe the drug may offer even greater benefits for people struggling with obesity, a condition linked to numerous chronic health issues including diabetes, heart disease, and joint problems.

    What makes these findings especially encouraging is the possibility of achieving surgery-level results through a non-invasive treatment. For patients who are not candidates for bariatric surgery, or who wish to avoid its risks and recovery time, a highly effective medication could represent a life-changing alternative. Researchers and clinicians note that having multiple effective options allows doctors to better tailor treatment plans to individual patient needs and preferences.

    The development of retatrutide reflects the broader momentum in peptide-based therapeutics, where scientists continue to refine and improve upon earlier breakthroughs. As more data emerges from ongoing trials, researchers will be watching closely to understand long-term safety, durability of results, and how this treatment compares with existing options over extended use.

    While still in the research and development pipeline, retatrutide’s early results offer a hopeful glimpse into the future of obesity treatment—one where significant, sustained weight loss may be achievable without surgery for a growing number of patients. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery – UCHealth